Frequently Asked Questions

The NeuroMotor Pen test is a digital assessment conducted using a pen-like sensor device on a tablet to evaluate cognitive and movement-related symptoms.

The platform supports multiple testing scenarios. A battery of tests designed for cognitive assessment takes less than 3 minutes and a combined battery for cognition and fine movement around 15 minutes.

Yes, the test is completely non-invasive and safe. The handheld device is tested to medical safety standards.

The assessment is designed to reduce testing time while providing highly accurate clinical data.

The platform supports multiple testing scenarios. A battery of tests designed for cognitive assessment takes less than 3 minutes and a combined battery for cognition and fine movement around 15 minutes.

Yes, the test can be conducted by trained non-experts, helping reduce specialist time.

Results help providers support diagnostic, prognostic, and treatment-related clinical decisions.

Yes. In order to make a diagnosis or monitoring response to treatment, it is crucial that the symptoms can first of all be accurately quantified. This is the first essential step. To this end, we record a very rich data set from sensors integrated within the NeuroMotor Pen. Based on micro movements interpreted by clinically proven algorithms, biomarkers are derived allowing quantification of both cognitive and motor symptoms.

Importantly, the digital biomarkers combine real physiology combined with established pen and paper based tests for which the sensitivity and specificity was improved. Clinical users can get access to the underlying data, which provides proof of validity and avoidance of any black box AI.

Once the symptoms are objectively quantified and with an accuracy beyond what is possible through observation and less sensitive wearable tech for movement disorders, the NeuroMotor Pen platform provides decision support with separate algorithms with applied AI.

Decision support includes two types of algorithms: decision support for interpretation of complex symptoms to aid in differential diagnostic decision making & decision support for symptom tracking to understand treatment response.

Yes. The NeuroMotor Pen micro movement data enables to quantify a broad range of movement symptoms that could previously not be accurately measured in any way. The NeuroMotor Pen measures vigilance and cognitive symptoms, based on widely used pen and paper bases assessment of higher functions that are essential for everyday living tasks.

The motor and cognitive symptoms can also be concurrently recorded to assess if slower movement is due to for example dopamine deficiency in Parkinson’s only or if there is a sensori-motor (cognitive) component.

Wearable movement disorder tracking tools can be helpful to get a sense of how well patients are doing away from the clinic. However, there are known challenges with implementation and interpretation of continuous measurement that have limited accuracy, which reduces the clinical relevance.

We believe that the diagnostic and monitoring challenges can only be resolved by developing tech from the ground up, incorporating novel sensors and analytics. In other words, we had to start with the problem to create a technical solution rather than starting with available tech.

Yes, users confirm that they find the assessments easy and enjoyable and confirm they can use the device at home.